anti-TNFRSF10B (TNFRSF10B) Antikörper

Bezeichnung:
anti-Tumor Necrosis Factor Receptor Superfamily, Member 10b Antikörper (TNFRSF10B)
Auf www.antikoerper-online.de finden Sie aktuell 373 Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B) Antikörper von 35 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen TNFRSF10B Proteine (47) und TNFRSF10B Kits (14) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 454 TNFRSF10B Produkte verfügbar.
Synonyme:
CD262, DR5, KILLER, KILLER/DR5, Ly98, MK, TNFRSF10B, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, xDR-M1, xDR-M2, ZTNFR9
Alle Antikörper anzeigen Gen GeneID UniProt
TNFRSF10B 364420  
TNFRSF10B 8795 O14763
TNFRSF10B 21933 Q9QZM4

Alle Spezies anzeigen

Weitere Synonyme anzeigen

Meistgesuchte Reaktivitäten zu anti-TNFRSF10B (TNFRSF10B) Antikörper

Wählen Sie die Spezies und Applikation aus

anti-Rat (Rattus) TNFRSF10B Antikörper:

anti-Human TNFRSF10B Antikörper:

anti-Mouse (Murine) TNFRSF10B Antikörper:

Alle verfügbaren anti-TNFRSF10B Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Am meisten referenzierte anti-TNFRSF10B Antikörper

  1. Human Monoclonal TNFRSF10B Primary Antibody für FACS - ABIN4898055 : Peppa, Gill, Reynolds, Easom, Pallett, Schurich, Micco, Nebbia, Singh, Adams, Kennedy, Maini: Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. in The Journal of experimental medicine 2013 (PubMed)
    Zeige alle 13 Referenzen für 4898055

  2. Mouse (Murine) Polyclonal TNFRSF10B Primary Antibody für FACS, Neut - ABIN4900408 : Park, Wu, Choi, Najafi, Emami, Safa: P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. in Biochemical pharmacology 2006 (PubMed)
    Zeige alle 3 Referenzen für 4900408

  3. Human Monoclonal TNFRSF10B Primary Antibody für FACS - ABIN1106166 : Mérino, Lalaoui, Morizot, Schneider, Solary, Micheau: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. in Molecular and cellular biology 2006 (PubMed)
    Zeige alle 2 Referenzen für 1106166

  4. Human Monoclonal TNFRSF10B Primary Antibody für FACS - ABIN238400 : Corallini, Milani, Nicolin, Secchiero: TRAIL, caspases and maturation of normal and leukemic myeloid precursors. in Leukemia & lymphoma 2006 (PubMed)

  5. Human Polyclonal TNFRSF10B Primary Antibody für WB - ABIN2792103 : Baritaki, Suzuki, Umezawa, Spandidos, Berenson, Daniels, Penichet, Jazirehi, Palladino, Bonavida: Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. in Journal of immunology (Baltimore, Md. : 1950) 2008 (PubMed)

  6. Human Polyclonal TNFRSF10B Primary Antibody für WB - ABIN222914 : Erster, Mihara, Kim, Petrenko, Moll: In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. in Molecular and cellular biology 2004 (PubMed)

Weitere Antikörper gegen TNFRSF10B Interaktionspartner

Human Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B) Interaktionspartner

  1. Study provides direct biophysical evidence that Death Receptor 5 disulfide-linked transmembrane (TM)-dimers open in response to ligand binding. Then, to probe the importance of the closed-to-open TM domain transition in the overall energetics of receptor activation, point-mutants (alanine to phenylalanine) in the predicted, tightly packed TM domain dimer interface were designed and tested.

  2. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer cells and xenograft tumors.

  3. Oridonin analog CYD (zeige CYBB Antikörper)-6-28 induces apoptosis at least partially by inducing the expression of death receptor 5 in breast neoplasms.

  4. The authors show that cholesterol is necessary for the covalent dimerization of DR5 transmembrane domains.

  5. Mono treatment with lexatumumab was not sufficient to induce apoptosis in pancreatic cancer cells, whereas focal adhesion kinase inhibitor PF573228 significantly sensitized lexatumumab-induced apoptosis. Western blotting analysis revealed that lexatumumab and PF573228 combination treatment increased death receptor 5 but decreased Bcl-xL (zeige BCL2L1 Antikörper) expression.

  6. We demonstrate that PBOX-15 can enhance TRAIL-induced apoptosis by upregulation of DR5, reduction of cellular mitochondrial potential, activation of the caspase (zeige CASP3 Antikörper) cascade and downregulation of PI3K (zeige PIK3CA Antikörper)/Akt (zeige AKT1 Antikörper), c-FLIP (zeige CFLAR Antikörper), Mcl-1 (zeige MCL1 Antikörper) and IAP (zeige ALPI Antikörper) survival pathways

  7. The nanovectorization of TRAIL enhanced its binding to both DR4 (zeige HLADRB4 Antikörper) and DR5 receptors at 37 degrees C and could potentially sensitized cancer cells to TRAIL induced apoptosis through simultaneous activation of DR4 (zeige HLADRB4 Antikörper) and DR5 as described in this paper for the non-small lung carcinoma cell line (H1703), the two hepatocarcinoma cell lines (SK-Hep1, HUH) and the colon carcinoma cell line (HCT116WT).

  8. we found that CQ decreased the expression of Cbl (zeige CBL Antikörper), an E3 ligase of DR5, and knock-down of Cbl (zeige CBL Antikörper) markedly enhanced DR5 up-regulation. Other lysosomal inhibitors, including monensin and nigericin, also up-regulated DR5 and sensitized TRAIL-mediated apoptosis

  9. MG132 possesses anti-gallbladder cancer potential that correlate with regulation of DR5-dependent pathway.

  10. Edelfosine also activated p38MAPK (MAPK14 (zeige MAPK14 Antikörper)), and edelfosine-mediated rhTRAIL sensitization was partially regulated by a p38 (zeige CRK Antikörper)-mediated decrease in mitochondrial membrane potential. This study suggests a novel therapeutic strategy targeting gastric cancer cells by using the combination of edelfosine and TRAIL.

Mouse (Murine) Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B) Interaktionspartner

  1. Authors demonstrate, for the first time, expression of TNF-related apoptosis-inducing ligand (TRAIL (zeige TNFSF10 Antikörper)) and its signaling death receptor 5 (DR5) in the murine inner ear.

  2. Malignant transformation in the endometrium is related to reduction of membrane DR4 (zeige HLADRB4 Antikörper) and DR5 expression.

  3. TRAIL expression by osteoclast-like cells is increased in the presence of RANKL (zeige TNFSF11 Antikörper) and after scraping; DcR2 (zeige TNFRSF10D Antikörper) expression peaks at 24 hours, and and decreases at 5 days; DR5 expression peaks at 5 days

  4. Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34 (zeige CD34 Antikörper)(+) cells.

  5. TRAIL-DR5 interaction promoted malignant behaviors of B16F10 cells.

  6. results suggest that the transmembrane domains together with their adjacent stalk regions can play a major role in control of death receptor activation thereby contributing to cell type specific differences in TRAILR1 and TRAILR2 signaling

  7. DR5 is selectively expressed by neuroprogenitor cells and newborn neurons.

  8. Results suggest that excessive iodine could induce TRAIL and DR5 abnormal expression in thyroid. TRAIL band with DR5 to promote follicular cells apoptosis thus mediate thyroid destruction in EAT.

  9. NK cells inhibit dendritic cell cross-priming, but not direct priming, in a TRAIL/DR5-dependent manner.

  10. Antibody-based therapy targeting DR5 is an efficient strategy not only to eliminate TRAIL-sensitive tumor cells.

TNFRSF10B Antigen-Profil

Beschreibung des Gens

The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for this gene.

Alternative names and synonyms associated with TNFRSF10B

  • tumor necrosis factor receptor superfamily, member 10b (Tnfrsf10b) Antikörper
  • tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B) Antikörper
  • tumor necrosis factor receptor superfamily, member 10b (tnfrsf10b-b) Antikörper
  • tumor necrosis factor receptor superfamily, member 10b (tnfrsf10b) Antikörper
  • CD262 Antikörper
  • DR5 Antikörper
  • KILLER Antikörper
  • KILLER/DR5 Antikörper
  • Ly98 Antikörper
  • MK Antikörper
  • TNFRSF10B Antikörper
  • TRAIL-R2 Antikörper
  • TRAILR2 Antikörper
  • TRICK2 Antikörper
  • TRICK2A Antikörper
  • TRICK2B Antikörper
  • TRICKB Antikörper
  • xDR-M1 Antikörper
  • xDR-M2 Antikörper
  • ZTNFR9 Antikörper

Bezeichner auf Proteinebene für TNFRSF10B

tumor necrosis factor receptor superfamily, member 10b , death receptor-M2 , death receptor-M1 , Fas-like protein , TNF-related apoptosis-inducing ligand receptor 2 , apoptosis inducing protein TRICK2A/2B , apoptosis inducing receptor TRAIL-R2 , cytotoxic TRAIL receptor-2 , death domain containing receptor for TRAIL/Apo-2L , death receptor 5 , p53-regulated DNA damage-inducible cell death receptor(killer) , tumor necrosis factor receptor superfamily member 10B , tumor necrosis factor receptor-like protein ZTNFR9 , KILLER/DR5 TRAIL death-inducing receptor

GENE ID SPEZIES
364420 Rattus norvegicus
282533 Bos taurus
404687 Xenopus laevis
404688 Xenopus laevis
448240 Xenopus (Silurana) tropicalis
742898 Pan troglodytes
8795 Homo sapiens
21933 Mus musculus
Ausgewählte Anbieter für anti-TNFRSF10B (TNFRSF10B) Antikörper
Haben Sie etwas anderes gesucht?